ADCY6 and heart failure: The subsequent FLOURISH trial, a double-blinded placebo-controlled, multicenter phase 3 trial of 536 patients, aims to decrease heart failure hospitalization rates and improve ejection fraction, while minimizing adverse events after intracoronary injection of the human adenovirus 5 encoding human AC6 (Ad5.